Document is current
Any future updates will be listed below
-
Authors
Fagiolini, Andrea
Mariano, Melissa Paulita
Biesheuvel, Egbert
Purushottamahanti, Pradeep
- License Information
-
More Information
Article History
Received: 15 July 2024
Accepted: 8 September 2024
First Online: 7 November 2024
Declarations
:
: Primary data from research on human or animal subjects were not used in the analyses for this paper. Secondary, deidentified and anonymized data from previously conducted clinical trials were utilized in this paper. Hence ethics approval has been deemed not required. Not all studies have been previously published. This post-hoc pooled analysis considered data from other clinical studies, therefore ethical considerations, including the Helsinki declaration on ethical considerations are not applicable.
: Andrea Fagiolini has received research grants and/or a paid consultant and/or a paid speaker of Angelini, Boehringer Ingelheim, Janssen, Biogen, Lundbeck, Mylan, Neuraxpharm, Otsuka, Pfizer, Recordati, Rovi, Sanofi Aventis, Viatris, Apsen, Glaxo Smith Kline, and Vifor. Melissa P Mariano is a paid consultant and/or a paid speaker of Johnson & Johnson, Otsuka Pharmaceutical, Viatris, and H. Lundbeck. Egbert Biesheuvel is a shareholder and an employee of Viatris, and a former employee of MSD. Pradeep Purushottamahanti is an employee of Viatris.
